Rare disease focus Recordati Rare Diseases concentrates on underserved rare disease patients, indicating continued potential in expanding specialty portfolio offerings and targeted outreach to patient advocacy groups and specialty pharmacies.

Acquisition momentum Recent acquisitions of Enjaymo from Sanofi and prior assets suggest an openness to inorganic growth; sales teams should explore cross-sell opportunities with newly integrated medicines and leverage consolidated IP in rare diseases.

US market expansion potential With a US-focused product like CYSTADROPS and ongoing portfolio growth, there is opportunity to scale direct sales and payer engagement in North America, supported by corporate consolidation and new clinical programs.

Strategic partnerships Recent collaboration for a hybrid livestream indicates a receptiveness to strategic partnerships and co-marketing; explore co-promotional, speakership, and digital marketing alliances with specialty distributors and patient groups.

Financial health signals Revenue in the mid-range and a clear growth trajectory from acquisitions point to a favorable backdrop for expanding field forces, payer negotiations, and regional market expansion initiatives.